Serum FGF21 levels in adult m.3243A>G carriers: Clinical implications

Neurology

Volumn 83, Issue 2, 2014, Pages 125-133

  Koene, Saskia ^a   De Laat, Paul ^a   Van Tienoven, Doorlène H ^b   Vriens, Dennis ^c   Brandt, André M ^b   Sweep, Fred C G J ^b   Rodenburg, Richard J T ^a   Donders, A Rogier T ^d   Janssen, Mirian C H ^a   Smeitink, Jan A M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Laboratory Medicine   (Netherlands)

^c Nuclear Medicine   (Netherlands)

^d Health Evidence   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR;

ADULT; AGED; ARTICLE; BRAIN DISEASE; CARDIOMYOPATHY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EPITHELIUM CELL; FEMALE; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; GENE MUTATION; HEARING IMPAIRMENT; HETEROPLASMY; HETEROZYGOTE; HUMAN; KIDNEY FUNCTION; KIDNEY GRAFT; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MELAS SYNDROME; MYOPATHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; URINE; VERY ELDERLY; BLOOD; CHEMISTRY; COHORT ANALYSIS; GENETICS; MITOCHONDRIAL ENCEPHALOMYOPATHY; MITOCHONDRIAL MYOPATHY; MUTATION; PROGNOSIS;

ADULT; BIOLOGICAL MARKERS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FIBROBLAST GROWTH FACTORS; FOLLOW-UP STUDIES; HETEROZYGOTE; HUMANS; LEUKOCYTES; MALE; MITOCHONDRIAL DISEASES; MITOCHONDRIAL ENCEPHALOMYOPATHIES; MITOCHONDRIAL MYOPATHIES; MUTATION; PROGNOSIS;

EID: 84903984107     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000578     Document Type: Article

References (24)

1. Ruiter EM, Siers MH, van den Elzen C, et al. The mitochondrial 13513G.A mutation is most frequent in Leigh syndrome combined with reduced complex I activity, optic atrophy and/or Wolff-Parkinson-White. Eur J Hum Genet 2007;15: 155-161.
2. Janssen AJ, Schuelke M, Smeitink JA, et al. Muscle 3243A/G mutation load and capacity of the mitochondrial energy-generating system. Ann Neurol 2008;63: 473-481.
3. Sproule DM, Kaufmann P. Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes: basic concepts, clinical phenotype, and therapeutic management of MELAS syndrome. Ann NY Acad Sci 2008;1142: 133-158.
4. Laloi-Michelin M, Meas T, Ambonville C, et al. The clinical variability of maternally inherited diabetes and deafness is associated with the degree of heteroplasmy in blood leukocytes. J Clin Endocrinol Metab 2009;94: 3025-3030.
5. de Laat P, Koene S, van den Heuvel LP, Rodenburg RJ, Janssen MC, Smeitink JA. Clinical features and heteroplasmy in blood, urine and saliva in 34 Dutch families carrying the m.3243A.G mutation. J Inherit Metab Dis 2012;35: 1059-1069.
6. Suomalainen A, Elo JM, Pietilainen KH, et al. FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. Lancet Neurol 2011;10: 806-818.
7. Crooks DR, Natarajan TG, Jeong SY, et al. Elevated FGF21 secretion, PGC-1alpha and ketogenic enzyme expression are hallmarks of iron-sulfur cluster depletion in human skeletal muscle. Hum Mol Genet 2014;23: 24-39.
8. Davis RL, Liang C, Edema-Hildebrand F, et al. Fibroblast growth factor 21 is a sensitive biomarker of mitochondrial disease. Neurology 2013;81: 1819-1826.
9. Salehi MH, Kamalidehghan B, Houshmand M, Aryani O, Sadeghizadeh M, Mossalaeie MM. Association of fibroblast growth factor (FGF-21) as a biomarker with primary mitochondrial disorders, but not with secondary mitochondrial disorders (Friedreich ataxia). Mol Biol Rep 2013;40: 6495-6499.
10. Su SL, Wang WF, Wu SL, et al. FGF21 in ataxia patients with spinocerebellar atrophy and mitochondrial disease. Clin Chim Acta 2012;414: 225-227.
11. Schaefer AM, Phoenix C, Elson JL, McFarland R, Chinnery PF, Turnbull DM. Mitochondrial disease in adults: a scale to monitor progression and treatment. Neurology 2006;66: 1932-1934.
12. Rahman S, Poulton J, Marchington D, Suomalainen A. Decrease of 3243 A/G mtDNA mutation from blood in MELAS syndrome: a longitudinal study. Am J Hum Genet 2001;68: 238-240.
13. Tyynismaa H, Raivio T, Hakkarainen A, et al. Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins. J Clin Endocrinol Metab 2011;96: E351-E355.
14. Fazeli PK, Misra M, Goldstein M, Miller KK, Klibanski A. Fibroblast growth factor-21 may mediate growth hormone resistance in anorexia nervosa. J Clin Endocrinol Metab 2010;95: 369-374.
15. Dostalova I, Kavalkova P, Haluzikova D, et al. Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab 2008;93: 3627-3632.
16. Galman C, Lundasen T, Kharitonenkov A, et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 2008;8: 169-174.
17. Hojman P, Pedersen M, Nielsen AR, et al. Fibroblast growth factor-21 is induced in human skeletal muscles by hyperinsulinemia. Diabetes 2009;58: 2797-2801.
18. Mashili FL, Austin RL, Deshmukh AS, et al. Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. Diabetes Metab Res Rev 2011;27: 286-297.
19. Domingo P, Gallego-Escuredo JM, Domingo JC, et al. Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients. AIDS 2010;24: 2629-2637.
20. Semba RD, Sun K, Egan JM, Crasto C, Carlson OD, Ferrucci L. Relationship of serum fibroblast growth factor 21 with abnormal glucose metabolism and insulin resistance: the Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2012;97: 1375-1382.
21. Hosszufalusi N, Karcagi V, Horvath R, et al. A detailed investigation of maternally inherited diabetes and deafness (MIDD) including clinical characteristics, C-peptide secretion, HLA-DR and -DQ status and autoantibody pattern. Diabetes Metab Res Rev 2009;25: 127-135.
22. Lin Z, Zhou Z, Liu Y, et al. Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS One 2011;6: e18398.
23. Lee P, Brychta RJ, Linderman J, Smith S, Chen KY, Celi FS. Mild cold exposure modulates fibroblast growth factor 21 (FGF21) diurnal rhythm in humans: relationship between FGF21 levels, lipolysis, and cold-induced thermogenesis. J Clin Endocrinol Metab 2013;98: E98-E102.
24. Foo JP, Aronis KN, Chamberland JP, Paruthi J,Moon HS, Mantzoros CS. Fibroblast growth factor 21 levels in young healthy females display day and night variations and are increased in response to short-term energy deprivation through a leptin-independent pathway. Diabetes Care 2013;36: 935-942.